98%
921
2 minutes
20
Purpose: To appropriately adopt the organ preservation approach, including subsequent chemoradiotherapy (CRT) in patients who respond to neoadjuvant chemotherapy (NAC), the distribution of residual disease, including pathological lymph nodes (LNs) and recurrence site, needs to be recognized preoperatively. This study was designed to evaluate whether endoscopic response evaluation can predict residual tumor distribution.
Methods: Patients with esophageal squamous cell carcinoma who underwent transthoracic esophagectomy (TTE) were retrospectively reviewed. Endoscopic responder (ER) to NAC was defined according to primary tumor endoscopic findings. Recurrence-free survival (RFS), overall survival (OS), and residual tumor patterns were compared between groups.
Results: Of 193 patients, 40 (20%) were classified as ER. ERs showed significantly better RFS and OS. The pN location was found within the primary tumor and cN field in 88% of ERs, which was significantly higher than non-ERs at 63% (p = 0.004). Furthermore, the postoperative recurrence incidence in the distant organ was significantly lower in the ERs than the non-ERs (8%, 32%, respectively, p = 0.002). Residual disease, including postoperative initial recurrence, existed within the same field as the primary tumor and cN in 88% of ERs, significantly higher than 42% in the non-ERs (p < 0.001).
Conclusions: Endoscopic response evaluation can preoperatively predict distribution of residual tumors after NAC, which could help radiation field selection in subsequent definitive CRT when patients prefer to omit TTE. Along with improvements in NAC response rate, this could facilitate organ preservation in patients who respond to NAC.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1245/s10434-021-11009-7 | DOI Listing |
Front Endocrinol (Lausanne)
September 2025
Department of Endocrinology and Nutrition, Hospital Clínico San Carlos Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
Introduction: Dumping syndrome (DS) and postprandial hypoglycemia (PPH) are challenging complications encountered after Roux-en-Y gastric bypass (RYGB). Surgical revision is often the next therapeutic step when pharmacological and dietary treatments fail to control DS and PPH. Endoscopic argon plasma coagulation (APC) is a less invasive alternative that reduces the diameter of the gastrojejunal anastomosis (GJA).
View Article and Find Full Text PDFScand J Gastroenterol
September 2025
Department of Abdominal Surgery, University Hospital Leuven, Leuven, KU, Belgium.
Background And Aims: Patients with Crohn's disease (CD) undergoing ileocolic resection (ICR) develop higher postoperative C-reactive protein (CRP) levels compared to colorectal cancer (CRC) patients, suggesting an increased postoperative inflammatory response. This study investigates whether postoperative C-reactive protein (CRP) levels are associated with endoscopic recurrence (ER) after ICR.
Methods: All CD patients who underwent ICR between 2007 and 2022 at two referral centers were identified from prospectively maintained databases.
Nutr J
September 2025
Department of Gastroenterology and Hepatology, Hangzhou Red Cross Hospital, 208 Huancheng Dong Road, Hangzhou, 310003, Zhejiang Province, China.
Background: The potential association between dietary inflammatory index (DII) and colorectal cancer (CRC) risk, as well as colorectal adenomas (CRA) risk, has been extensively studied, but the findings remain inconclusive. We conducted this systematic review and dose-response meta-analysis to investigate the relationship between the DII and CRC and CRA.
Methods: We comprehensively searched the PubMed, Embase, Cochrane Library, and Web of Science databases for cohort and case-control studies reporting the relationship between DII and CRA, or between DII and CRC, as of 15 July 2025.
Global Spine J
September 2025
Hôpital de Chicoutimi, Chicoutimi, QC, Canada.
Clin Gastroenterol Hepatol
September 2025
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. Electronic address:
Background And Aims: Infliximab and ustekinumab clearance have been suggested as predictors of disease activity in patients with inflammatory bowel diseases. We aimed to investigate the benefits of clearance monitoring for predicting endoscopic outcomes in patients with Crohn's disease (CD).
Methods: Data from patients with moderate-to-severe CD starting infliximab (n=108) and ustekinumab (n=80) therapy were repurposed.